How have PARP inhibitors changed maintenance therapy for advanced ovarian cancer? Join Dr Michael Birrer and Dr Ursula Matulonis as they discuss recent clinical data related to the use of PARP inhibitors in maintenance therapy for advanced ovarian cancer, and highlight strategies to effectively prevent and manage treatment-related adverse effects.
This activity is jointly provided by Postgraduate Institute for Medicine and Spire Learning.
This activity is supported by an independent educational grant from Tesaro, a GSK company.
Click on this link to access the program: